One-Step Method for Instant Generation of Advanced Allogeneic NK Cells
Name:
Lee_et_al-2018-Advanced_Science.pdf
Size:
4.620Mb
Format:
PDF
Description:
Final Published version
Affiliation
Univ Arizona, Coll Med, Dept Surg, Div Cardiothorac SurgIssue Date
2018-11-01
Metadata
Show full item recordPublisher
WILEYCitation
Lee, D. Y., Lim, K. S., Valencia, G. M., Jung, M., Bull, D. A., Won, Y.‐W., Adv. Sci. 2018, 5, 1800447. https://doi.org/10.1002/advs.201800447Journal
ADVANCED SCIENCERights
© 2018 The Authors. Published by WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim. This is an open access article under the terms of the Creative Commons Attribution License.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Conventional combinatorial anticancer therapy has shown promising outcomes; still, a significant interest in developing new methods to reinforce and possibly merge chemotherapy and immunotherapy persists. Here, a new one-step method that immediately modifies immune cells into a targeted form of chemoimmunotherapy through spontaneous and rapid incorporation of hydrophobized antibody-drug conjugates (ADCs) on the surface of immune cells is presented. Therapeutic objectives of this approach include targeted delivery of a potent chemotherapeutic agent to avoid adverse effects, enhancing the mobilization of infused immune cells toward tumor sites, and preserving the intense cytotoxic activities of immune cells against tumor cells. The embedding of hydrophobized ADCs on the immune cell membrane using the strategy in this study provides noninvasive, nontoxic, and homogenous modifications that transiently arm immune cells with highly potent cytotoxic drugs targeted toward cancer cells. The resulting surface-engineered immune cells with ADCs significantly suppress the tumor growth and drive the eradication of target cancer cells through combinatorial anticancer effects. This novel strategy allows convenient and timely preparation of advanced chemoimmunotherapy on a single immune cell to treat various types of cancer.Note
Open access journalISSN
2198-3844PubMed ID
30479915Version
Final published versionSponsors
National Heart, Lung, and Blood Institute of the National Institutes of Health [R01HL138242]Additional Links
https://onlinelibrary.wiley.com/doi/full/10.1002/advs.201800447ae974a485f413a2113503eed53cd6c53
10.1002/advs.201800447
Scopus Count
Collections
Except where otherwise noted, this item's license is described as © 2018 The Authors. Published by WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim. This is an open access article under the terms of the Creative Commons Attribution License.
Related articles
- Synergistic Chemo-Immunotherapy: Recombinant Fusion Protein-Based Surface Modification of NK Cell for Targeted Cancer Treatment.
- Authors: Lim SY, Kim L, Kim H, Park JA, Yun J, Lim KS
- Issue date: 2024 Sep 8
- Combinatorial prospects of nano-targeted chemoimmunotherapy.
- Authors: Da Silva CG, Rueda F, Löwik CW, Ossendorp F, Cruz LJ
- Issue date: 2016 Mar
- Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
- Authors: Hong Y, Nam SM, Moon A
- Issue date: 2023 Mar
- Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer.
- Authors: Domb C, Garcia JA, Barata PC, Mendiratta P, Rao S, Brown JR
- Issue date: 2024 Jan-Dec
- Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment.
- Authors: Nader-Marta G, Molinelli C, Debien V, Martins-Branco D, Aftimos P, de Azambuja E, Awada A
- Issue date: 2023

